Data Sources: PubMed, Cochrane Library, PsycINFO, CINAHL, EMBASE, FDA website, and clinical trials registries (January 1, 1970, to March 1, 2014). The NNT to prevent return to any drinking for acamprosate was 12 (95% CI, 8 to 26; risk difference [RD], 0.09; 95% CI, 0.14 to 0.04) and was 20 (95% CI, 11 to 500; RD, 0.05; 95% CI, 0.10 to 0.002) for oral naltrexone (50 mg/d).

READ FULL ARTICLE Curated publisher From jama.jamanetwork.com